Please try another search
For the six months ended 30 June 2020, Aslan Pharmaceuticals Ltd revenues decreased from NT$92.4M to NT$0K. Net loss decreased 45% to NT$209.9M. Revenues reflect a decrease in demand for the Company's products and services due to unfavorable market conditions. Lower net loss reflects Research and Development Expenses decrease of 58% to NT$127.3M (expense), General and Administrative Expenses decrease of 35% to NT$83.6M (expense).
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Total Revenue | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0.55 | 0 |
Operating Income | -109.51 | -101.3 | -891.64 | -163.97 |
Net Income | -117.85 | -92.07 | -908.12 | -161.78 |
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Total Assets | 440.33 | 546.02 | 699.39 | 1005.19 |
Total Liabilities | 698 | 689.97 | 749.63 | 595.79 |
Total Equity | -257.67 | -143.95 | -50.24 | 409.4 |
Period Ending: | Jun 30, 2020 | Mar 31, 2020 | Dec 31, 2019 | Sep 30, 2019 |
---|---|---|---|---|
Period Length: | 6 Months | 3 Months | 12 Months | 9 Months |
Cash From Operating Activities | -247.09 | -158.47 | -796.12 | -644.17 |
Cash From Investing Activities | 0.01 | 0.01 | 0.17 | 0.12 |
Cash From Financing Activities | -3.88 | -1.97 | 583.68 | -5.56 |
Net Change in Cash | -258.21 | -154.04 | -218.55 | -635.52 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review